Enzo

The company's clinical services revenues were down 34 percent year over year while product revenues ticked up 7 percent.

Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.

The company said that diagnostic testing volumes, product and royalty revenues, and clinical services revenues all fell year over year.

The firm said clinical services revenues fell during the quarter due to reduced insurance reimbursement payments and mix of testing in the prior year.

After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.

The firm said the decline in Q4 revenues was due to an account loss as well as lower insurance reimbursement and shifts away from high-value genetic testing.

A brief recap of Genetics/Genomics news the week of Aug 31, 2018: Perosnalize Medicine Coalition, Enzo Biochem, Hoosier Cancer Research Network, Scor Global Life, and ALCF

Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.